Skip to main content
SpringerLink
Log in

Aktuelle Therapiestrategien bei follikulären Lymphomen

Current therapeutic strategies for follicular lymphoma

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Follikuläre Lymphome sind nach den diffus-großzelligen B-Zell-Lymphomen die zweithäufigste Lymphomentität. Ihr klinischer Verlauf ist in der Regel langsam progredient, sodass sie zu den indolenten Lymphomen gezählt werden. Bei den wenigen Patienten, bei denen die Erkrankung in einem frühen Stadium I oder II diagnostiziert wird, ist eine Strahlentherapie indiziert. In den fortgeschrittenen Stadien III und IV ist bei fehlender klinischer Symptomatik eine Watch-and-wait-Strategie angezeigt. Bei Vorliegen einer Behandlungsindikation ist eine Immunchemotherapie mit nachfolgender 2-jähriger Erhaltungstherapie mit Rituximab aktueller Standard.

Abstract

Follicular lymphomas are the second most frequent lymphoma entity following diffuse large cell B-cell lymphoma. The clinical course is slowly progressive so that they belong to the group of indolent lymphomas. For the few patients where the disease is diagnosed in localized stages I or II radiotherapy is indicated. In advanced stages III and IV a watch and wait strategy is indicated when there is a lack of clinical symptoms. If treatment is indicated immunochemotherapy followed by a 2-year rituximab maintenance comprises the standard of care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Advani R, Rosenberg SA, Horning SJ (2004) Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22:1454–1459

    Article  PubMed  Google Scholar 

  2. Ardeshna KM, Qian W, Smith P et al (2010) An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis. ASH Annual Meeting Abstracts 116:6

    Google Scholar 

  3. Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516–522

    Article  PubMed  CAS  Google Scholar 

  4. Buske C, Hoster E, Dreyling M et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504–1508

    Article  PubMed  CAS  Google Scholar 

  5. Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101–106

    Article  PubMed  CAS  Google Scholar 

  6. Deconinck E, Foussard C, Milpied N et al (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105:3817–3823

    Article  PubMed  CAS  Google Scholar 

  7. Dreyling M (2009) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):119–120

    Article  PubMed  Google Scholar 

  8. Dreyling M, Trumper L, Von Schilling C et al (2007) Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma – role of radioimmunotherapy. Ann Hematol 86:81–87

    Article  PubMed  CAS  Google Scholar 

  9. Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003–4008

    Article  PubMed  CAS  Google Scholar 

  10. Fowler NH, Mclaughlin P, Hagemeister FB et al (2010) Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin’s lymphoma. ASCO Meeting Abstracts 28:8036

    Google Scholar 

  11. Gyan E, Foussard C, Bertrand P et al (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 yrs. Blood 113:995–1001

    Article  PubMed  CAS  Google Scholar 

  12. Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849

    PubMed  CAS  Google Scholar 

  13. Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986–1992

    Article  PubMed  CAS  Google Scholar 

  14. Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–3732

    Article  PubMed  CAS  Google Scholar 

  15. Hochster H, Weller E, Gascoyne RD et al (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607–1614

    Article  PubMed  CAS  Google Scholar 

  16. Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441–449

    Article  PubMed  CAS  Google Scholar 

  17. Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004–4013

    Article  PubMed  CAS  Google Scholar 

  18. Lenz G, Dreyling M, Schiegnitz E et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667–2674

    Article  PubMed  CAS  Google Scholar 

  19. Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579–4586

    Article  PubMed  CAS  Google Scholar 

  20. Morschhauser F, Radford J, Van Hoof A et al (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164

    Article  PubMed  CAS  Google Scholar 

  21. Robert-Koch-Institut GDEKIDEVIZMD (2006) Krebs in Deutschland – Häufigkeiten und Trends. In:

  22. Rohatiner AZ, Gregory WM, Peterson B et al (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215–2223

    Article  PubMed  CAS  Google Scholar 

  23. Rummel MJ, Niederle N, Maschmeyer G et al (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the stil (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 114:405

  24. Salles G, Mounier N, De Guibert S et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112:4824–4831

    Article  PubMed  CAS  Google Scholar 

  25. Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 yrs in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42–51

    Article  PubMed  CAS  Google Scholar 

  26. Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706–714

    Article  PubMed  CAS  Google Scholar 

  27. Seer CSR (2007) SEER Surveillance, Epidemiology, and End Results. In: 1975–2004. SEER Cancer Stat Rev

  28. Seymour JF, Pro B, Fuller LM et al (2003) Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma. J Clin Oncol 21:2115–2122

    Article  PubMed  CAS  Google Scholar 

  29. Sinha R, Kaufman JL, Khoury HJ Jr et al (2009) The addition of bortezomib to modified R-CHOP as initial therapy for follicular NHL results in high CR rate and is well tolerated. Blood (ASH Annual Meeting Abstracts) 114:3718-

  30. Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265

    Article  PubMed  CAS  Google Scholar 

  31. Stuschke M, Hoederath A, Sack H et al (1997) Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fruhe Stadien. Cancer 80:2273–2284

    Article  PubMed  CAS  Google Scholar 

  32. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues

  33. Van Oers MH, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295–3301

    Article  Google Scholar 

  34. Vidal L, Gafter-Gvili A, Leibovici L et al (2009) Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 101:248–255

    Article  PubMed  CAS  Google Scholar 

  35. Witzens-Harig M, Hensel M, Unterhalt M et al (2011) Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer 11:87

    Article  PubMed  CAS  Google Scholar 

  36. Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463

    Article  PubMed  CAS  Google Scholar 

  37. Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88:386–401

    PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung hin: Unterstützung eines klinischen Forschungsprojekts durch Roche Pharma.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik III, Klinikum der Universität München – Campus Großhadern, Marchioninistraße 15, 81377, München, Deutschland

    C. Schmidt &  W. Hiddemann

  2. Abteilung Radioonkologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    K. Herfarth

Authors
  1. C. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Herfarth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Hiddemann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, C., Herfarth, K. & Hiddemann, W. Aktuelle Therapiestrategien bei follikulären Lymphomen. Onkologe 17, 799–805 (2011). https://doi.org/10.1007/s00761-011-2128-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-011-2128-3

Schlüsselwörter

Keywords

Search

Navigation